Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection.
Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection.
复制标题
DOI：
10.7759/cureus.10211
复制
发表时间：
2020-09-02
期刊：
影响因子：
--
通讯作者：
Eskander J
中科院分区：
文献类型：
--
作者：
Berger AA;Sherburne R;Urits I;Patel H;Eskander J
COVID-19是由SARS-CoV-2病毒引起的致命的全球大流行，到2020年5月，该病毒已直接导致美国至少95235人死亡。该病预后不良，在大流行高峰期，一般人群的死亡率高达21%，老年患者以及需要重症监护病房（ICU）护理的患者的死亡率要高得多。炎症在症状性COVID-19中的作用正在研究中，并假设高炎症是严重COVID-19疾病的致病因素。治疗选择有限，主要依赖于支持性护理。二十戊二烯乙基（IPE）是一种Omega-3脂肪酸衍生物，已被证明可显著降低心血管死亡率，并被用作他汀类药物治疗的辅助药物。虽然它已经被证明有消炎的作用，但目前还没有被用于这一目的。在这里，我们首次描述了使用IPE对COVID-19患者的成功治疗。
COVID-19 is a fatal, universal pandemic caused by the SARS-CoV-2 virus that has directly caused at least 95,235 deaths in the US by May 2020. It has a poor prognosis with a mortality rate as high as 21% in the general population at the height of the pandemic, a rate that is much higher in elderly patients, as well as those requiring intensive care unit (ICU) care. The role of inflammation in symptomatic COVID-19 is being studied, and it is hypothesized that hyper-inflammation is a causative factor in severe COVID-19 disease. Treatment options are limited and mostly rely on supportive care. Icosapent ethyl (IPE) is an Omega-3 fatty acid derivative that has been shown to significantly reduce cardiovascular mortality and is used as an adjunct to statin therapy. Though it has been shown to act as an anti-inflammatory, it is not currently indicated for that purpose. Here, we describe, for the first time, the successful treatment of a COVID-19 patient with IPE.
登录
查看更多内容
DOI：
10.1056/nejmoa2022926
发表时间：
2020-11-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
RECOVERY Collaborative Group;Horby P;Mafham M;Linsell L;Bell JL;Staplin N;Emberson JR;Wiselka M;Ustianowski A;Elmahi E;Prudon B;Whitehouse T;Felton T;Williams J;Faccenda J;Underwood J;Baillie JK;Chappell LC;Faust SN;Jaki T;Jeffery K;Lim WS;Montgomery A;Rowan K;Tarning J;Watson JA;White NJ;Juszczak E;Haynes R;Landray MJ
通讯作者：
Landray MJ
DOI：
10.1007/s40256-012-0002-3
发表时间：
2013-02
期刊：
American journal of cardiovascular drugs : drugs, devices, and other interventions
影响因子：
--
作者：
Bays HE;Ballantyne CM;Braeckman RA;Stirtan WG;Soni PN
通讯作者：
Soni PN
影响因子：
39
作者：
Weinberger, Daniel M.;Chen, Jenny;Viboud, Cecile
通讯作者：
Viboud, Cecile
DOI：
10.1016/j.ijantimicag.2020.106012
发表时间：
2020-08-01
影响因子：
10.8
作者：
Yu, Ran;Chen, Liang;Li, Peng
通讯作者：
Li, Peng
影响因子：
158.5
作者：
Guan, W.;Ni, Z.;Zhong, N.
通讯作者：
Zhong, N.